S&P 500   3,945.04 (-1.35%)
DOW   33,620.33 (-0.96%)
QQQ   282.98 (-1.62%)
AAPL   144.52 (-1.44%)
MSFT   246.36 (-1.53%)
META   115.06 (-6.02%)
GOOGL   97.17 (-2.32%)
AMZN   89.05 (-2.15%)
TSLA   179.40 (-1.67%)
NVDA   160.80 (-3.19%)
NIO   13.21 (+3.20%)
BABA   91.62 (+1.22%)
AMD   71.08 (-3.45%)
T   18.99 (+1.28%)
MU   54.28 (+0.44%)
CGC   3.66 (-15.28%)
F   13.16 (-1.64%)
GE   85.26 (+0.71%)
DIS   93.36 (-2.68%)
AMC   6.92 (-7.11%)
PYPL   72.29 (-1.81%)
PFE   49.70 (-2.03%)
NFLX   306.05 (-2.09%)
S&P 500   3,945.04 (-1.35%)
DOW   33,620.33 (-0.96%)
QQQ   282.98 (-1.62%)
AAPL   144.52 (-1.44%)
MSFT   246.36 (-1.53%)
META   115.06 (-6.02%)
GOOGL   97.17 (-2.32%)
AMZN   89.05 (-2.15%)
TSLA   179.40 (-1.67%)
NVDA   160.80 (-3.19%)
NIO   13.21 (+3.20%)
BABA   91.62 (+1.22%)
AMD   71.08 (-3.45%)
T   18.99 (+1.28%)
MU   54.28 (+0.44%)
CGC   3.66 (-15.28%)
F   13.16 (-1.64%)
GE   85.26 (+0.71%)
DIS   93.36 (-2.68%)
AMC   6.92 (-7.11%)
PYPL   72.29 (-1.81%)
PFE   49.70 (-2.03%)
NFLX   306.05 (-2.09%)
S&P 500   3,945.04 (-1.35%)
DOW   33,620.33 (-0.96%)
QQQ   282.98 (-1.62%)
AAPL   144.52 (-1.44%)
MSFT   246.36 (-1.53%)
META   115.06 (-6.02%)
GOOGL   97.17 (-2.32%)
AMZN   89.05 (-2.15%)
TSLA   179.40 (-1.67%)
NVDA   160.80 (-3.19%)
NIO   13.21 (+3.20%)
BABA   91.62 (+1.22%)
AMD   71.08 (-3.45%)
T   18.99 (+1.28%)
MU   54.28 (+0.44%)
CGC   3.66 (-15.28%)
F   13.16 (-1.64%)
GE   85.26 (+0.71%)
DIS   93.36 (-2.68%)
AMC   6.92 (-7.11%)
PYPL   72.29 (-1.81%)
PFE   49.70 (-2.03%)
NFLX   306.05 (-2.09%)
S&P 500   3,945.04 (-1.35%)
DOW   33,620.33 (-0.96%)
QQQ   282.98 (-1.62%)
AAPL   144.52 (-1.44%)
MSFT   246.36 (-1.53%)
META   115.06 (-6.02%)
GOOGL   97.17 (-2.32%)
AMZN   89.05 (-2.15%)
TSLA   179.40 (-1.67%)
NVDA   160.80 (-3.19%)
NIO   13.21 (+3.20%)
BABA   91.62 (+1.22%)
AMD   71.08 (-3.45%)
T   18.99 (+1.28%)
MU   54.28 (+0.44%)
CGC   3.66 (-15.28%)
F   13.16 (-1.64%)
GE   85.26 (+0.71%)
DIS   93.36 (-2.68%)
AMC   6.92 (-7.11%)
PYPL   72.29 (-1.81%)
PFE   49.70 (-2.03%)
NFLX   306.05 (-2.09%)
NASDAQ:OPK

OPKO Health - OPK Stock Forecast, Price & News

$1.39
-0.03 (-2.11%)
(As of 12/6/2022 12:05 PM ET)
Add
Compare
Today's Range
$1.37
$1.42
50-Day Range
$1.40
$2.01
52-Week Range
$1.36
$5.25
Volume
37,707 shs
Average Volume
2.68 million shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

OPKO Health MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
186.7% Upside
$4.00 Price Target
Short Interest
Bearish
9.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$2.39 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.43) to ($0.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

382nd out of 1,023 stocks

Pharmaceutical Preparations Industry

161st out of 501 stocks

OPK stock logo

About OPKO Health (NASDAQ:OPK) Stock

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Receive OPK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OPKO Health and its competitors with MarketBeat's FREE daily newsletter.

OPK Stock News Headlines

Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top
Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
OPKO Health, Inc. (OPK.TA)
OPKO Health, Inc. (OPK)
Israel stocks higher at close of trade; TA 35 up 1.20%
See More Headlines
Receive OPK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OPKO Health and its competitors with MarketBeat's FREE daily newsletter.

OPK Company Calendar

Last Earnings
10/28/2021
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:OPK
CUSIP
68375N10
Employees
5,767
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+187.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-30,140,000.00
Pretax Margin
-29.11%

Debt

Sales & Book Value

Annual Sales
$1.77 billion
Cash Flow
$0.07 per share
Book Value
$2.47 per share

Miscellaneous

Free Float
456,117,000
Market Cap
$1.07 billion
Optionable
Optionable
Beta
1.62

Key Executives

  • Dr. Phillip Frost Ph.D. (Age 86)
    Chairman & CEO
    Comp: $971.6k
  • Dr. Jane H. Hsiao M.B.A. (Age 75)
    MBA, Ph.D., Vice Chairman & Chief Technical Officer
    Comp: $911.6k
  • Mr. Adam E. Logal (Age 44)
    Sr. VP, CFO, Chief Accounting Officer & Treasurer
    Comp: $911.6k
  • Mr. Steven D. Rubin Esq. (Age 62)
    J.D., Exec. VP of Admin. & Director
    Comp: $821.6k
  • Dr. Jon R. Cohen M.D. (Age 67)
    Advisor
    Comp: $1.74M
  • Dr. Elias Adam Zerhouni M.D. (Age 71)
    Pres & Vice Chairman
  • Dr. Arie Gutman (Age 68)
    Pres of API
  • Mr. James DeMarco
    Sr. VP of Pharmaceutical Sales
  • Dr. Akhtar Ashfaq
    Sr. VP of Clinical R&D and Medical Affairs
  • Ms. Jane Pine Wood Esq. (Age 59)
    J.D., Chief Legal Officer of Bio-Reference Laboratories













OPK Stock - Frequently Asked Questions

Should I buy or sell OPKO Health stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPK shares.
View OPK analyst ratings
or view top-rated stocks.

What is OPKO Health's stock price forecast for 2023?

2 brokerages have issued 12-month price targets for OPKO Health's stock. Their OPK share price forecasts range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 181.7% from the stock's current price.
View analysts price targets for OPK
or view top-rated stocks among Wall Street analysts.

How have OPK shares performed in 2022?

OPKO Health's stock was trading at $4.81 at the beginning of the year. Since then, OPK stock has decreased by 70.5% and is now trading at $1.42.
View the best growth stocks for 2022 here
.

When is OPKO Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our OPK earnings forecast
.

How were OPKO Health's earnings last quarter?

OPKO Health, Inc. (NASDAQ:OPK) announced its quarterly earnings results on Thursday, October, 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.05. The biotechnology company had revenue of $385.80 million for the quarter, compared to analysts' expectations of $302.27 million. OPKO Health had a negative trailing twelve-month return on equity of 14.79% and a negative net margin of 25.98%. The firm's revenue was down 9.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.04 earnings per share.

What is Philip Frost's approval rating as OPKO Health's CEO?

21 employees have rated OPKO Health Chief Executive Officer Philip Frost on Glassdoor.com. Philip Frost has an approval rating of 16% among the company's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OPKO Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).

What is OPKO Health's stock symbol?

OPKO Health trades on the NASDAQ under the ticker symbol "OPK."

Who are OPKO Health's major shareholders?

OPKO Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.21%), BlackRock Inc. (4.47%), Dimensional Fund Advisors LP (1.40%), State Street Corp (1.34%), Oracle Investment Management Inc. (0.66%) and Two Sigma Investments LP (0.37%). Insiders that own company stock include Anthony J Japour, Elias A Zerhouni, Gary J Nabel, Jon R Cohen, Phillip Md Et Al Frost, Robert J Shovlin and Steven D Rubin.
View institutional ownership trends
.

How do I buy shares of OPKO Health?

Shares of OPK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OPKO Health's stock price today?

One share of OPK stock can currently be purchased for approximately $1.42.

How much money does OPKO Health make?

OPKO Health (NASDAQ:OPK) has a market capitalization of $1.10 billion and generates $1.77 billion in revenue each year. The biotechnology company earns $-30,140,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis.

How many employees does OPKO Health have?

The company employs 5,767 workers across the globe.

How can I contact OPKO Health?

OPKO Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The official website for the company is www.opko.com. The biotechnology company can be reached via phone at (305) 575-4100, via email at mmiller@lhai.com, or via fax at 305-575-6015.

This page (NASDAQ:OPK) was last updated on 12/6/2022 by MarketBeat.com Staff